Tech Company Financing Transactions
Acepodia Funding Round
On 3/17/2021, Acepodia raised $47 million in Series B financing from 8VC, CDIB Capital and DEFTA Partners.
Transaction Overview
Company Name
Announced On
3/17/2021
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series B
Investors
Proceeds Purpose
The funding will be used to advance the company's lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1825 S. Grant St. 900
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Undisclosed
Website
Email Address
Overview
Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and inventor of Acepodia's core technology. Acepodia is a privately held biotechnology company focused on developing novel, targeted, allogeneic cell therapies to treat cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Patrick Yang
Chief Executive Officer
Sonny Hsiao
Chief Financial Officer
Jimmy Lai
VP - Bus. Development
Joseph McCracken
VP - Operations
Michael Kurman
VP - R & D
Mark Gilbert
VP - Regulatory Affairs
William Mackin
Browse more venture capital transactions:
Prev: 3/17/2021: Trullion venture capital transaction
Next: 3/17/2021: StrideBio venture capital transaction
Share this article
News on VC Transactions
We document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs